Adherence to Cysteamine Therapy Among Patients Diagnosed with Cystinosis in Saudi Arabia: A Prospective Cohort Study
by
Reem Algasem
1, 
Nedaa Zainy
1,
Essam Alsabban
2,
Hamad Almojalli
3,
Khalid Alhasan
3,
Tariq Ali
3,
Deiter Broering
3 and
Hassan Aleid
3,* 1
Department of Pharmacy, King Faisal Specialist Hospital and Research Centre, Riyadh P.O. Box 3354, Saudi Arabia
2
Department of Pediatric Nephrology, King Faisal Specialist Hospital and Research Centre, Riyadh P.O. Box 3354, Saudi Arabia
3
Department of Kidney and Pancreas Transplant, King Faisal Specialist Hospital and Research Centre, Riyadh P.O. Box 3354, Saudi Arabia
*
Author to whom correspondence should be addressed.
Pharmacy 2024, 12(4), 123; https://doi.org/10.3390/pharmacy12040123
Submission received: 17 June 2024
/
Revised: 20 July 2024
/
Accepted: 5 August 2024
/
Published: 8 August 2024
(This article belongs to the Section Pharmacy Practice and Practice-Based Research)
Abstract
:Cystinosis is a rare autosomal recessive disorder in which cystine crystals accumulate within the cellular lysosomes, causing damage to multiple organs. Due to challenges with the stringent cysteamine treatment regimen and side effects, adherence is often sub-optimal. This study aimed to assess the level of adherence to cysteamine therapy among cystinosis patients in Saudi Arabia and its impact on their quality of life. Electronic medical record data of 39 cystinosis patients from the Department of Nephrology at King Faisal Specialist Hospital and Research Center in Saudi Arabia were reviewed, and 25 patients were included in this study. Out of the 25 patients included in the final analysis, 64% (n = 16) were female. The mean age was 19.04 years. Almost all patients (23/25, 92%) were on oral IR cysteamine therapy, and 52% (13/25) were on topical cysteamine eye drop treatment. Of the 15 patients who responded to the Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire, only 4 (26.7%) were highly adherent to cysteamine therapy. Most of the respondents (7/15, 46.7%) showed a medium level of treatment adherence. Based on the medication possession ratio for oral cysteamine, only 6 out of 23 patients (26.1%) were found to be 96–100% adherent. For the cysteamine eye drops, only 5/13 patients (38.4%) were 76–95% adherent. The 36-Item Short Form Health Survey (SF-36) used to assess patients’ health-related outcomes showed that their quality of life was affected in the domains of ‘social functioning’ and ‘energy/fatigue.’ Despite a small sample size, this study shows sub-optimal adherence to cysteamine treatment in patients from Saudi Arabia. The possible reasons for low treatment adherence could be a high frequency of administration and treatment-related side effects.
1. Introduction
Cystinosis is a rare autosomal recessive disorder in which cystine crystals accumulate within the cellular lysosomes, resulting in damage to multiple organs [1]. It is caused by mutations in the cystinosin-encoding CTNS gene that disrupt the transportation of cystine out of the lysosomes. Cystine accumulation within the lysosomes is responsible for the clinical manifestations of cystinosis [2]. The primary clinical presentations of cystinosis include infantile nephropathic cystinosis, late-onset nephropathic cystinosis, and non-nephropathic ocular cystinosis [3]. Infantile nephropathic cystinosis is the most frequently diagnosed and the most severe form of cystinosis, manifesting as renal Fanconi syndrome that progresses to end-stage renal disease (ESRD) at a young age. Typically, the first extra-renal pathological finding in cystinosis patients is in the cornea in the form of cystine crystals [3]. Moreover, cystinosis is a systemic disorder, and organ systems like the endocrine, muscular, and central nervous systems are also affected, besides the kidneys and eyes.
The mainstay treatment for cystinosis is cysteamine, a cystine-depleting agent that has helped improve overall outcomes and life expectancy by delaying extra-renal manifestations and the progression to ESRD [1,4,5,6]. Cysteamine allows cystine to exit the lysosomes via transporter mechanisms other than cystinosin [2]. Although, unlike many other orphan diseases, treatment is available for cystinosis, its effectiveness relies on the extent of adherence, which has often been found to be sub-optimal, primarily due to challenges with the treatment regimen and gastrointestinal and other side effects like halitosis and sulfuric body odor [2,4,5]. Moreover, cysteamine treatment is not curative and must be initiated early and taken lifelong to ensure its therapeutic benefits are entirely utilized.
Cysteamine is available in immediate-release (IR) and delayed-release (DR) formulations. The IR formulation of cysteamine (CYSTAGON®), available in 50 mg and 150 mg capsules, has been approved for use in the US and Europe since 1994 and 1997, respectively [4,7,8]. The recommended oral dose of IR cysteamine in children up to 12 years is 1.3 g/m2/day (or 60 mg/kg/day) divided into four doses and increased gradually over four to six weeks. The maximum recommended dose is 1.95 g/m2/day or 90 mg/kg/day [7]. Approved by the FDA in 2013, the DR formulation PROCYSBI® was developed to address the frequent dosing challenges associated with the IR formulation. PROCYSBI® is available in 25 and 75 mg capsules, and the recommended dose is 1.3 g/m2/day in divided doses every 12 h [4,9]. However, the side effect profiles of the IR and DR cysteamine formulations are comparable and primarily include vomiting, abdominal pain, diarrhea, loss of appetite, drowsiness, and skin rash.
Corneal manifestations of cystinosis include photophobia, blepharospasm, corneal erosions, superficial punctate keratopathy, and band keratopathy. However, as the cornea is avascular, oral cysteamine fails to have any impact on corneal outcomes [10]. Topical application was found to be better suited for this purpose. Hence, an ophthalmic formulation, CYSTARAN®, was approved by the FDA in 2012 with the recommendation to administer one drop in each eye every waking hour [11]. A significant challenge with topically applied cysteamine is that it is rapidly cleared from the eye due to its inherent defense mechanisms, like reflex tearing, frequent blinking, and nasolacrimal drainage [12]. Thus, frequent administration of the ophthalmic cysteamine becomes inevitable to ensure efficient removal of corneal cystine crystals. Also, CYSTARAN® has stringent storage requirements; it must be stored in a freezer (−25 °C to −15 °C) and thawed for 24 h before use. The thawed ophthalmic solution must be used within 7 days [11]. Efforts to tweak the aqueous ophthalmic formulation, enabling more favorable storage requirements and less frequent administration, has led to the development of CYSTADROPS®, a more viscous formulation that was approved by the FDA in 2020 [13].
An open-label, phase 3, two-arm, multi-center RCT in France on cystinosis patients (≥2 years) by Liang et al. compared the efficacy of the viscous 0.55% cysteamine hydrochloride ophthalmic formulation with the standard 0.10% cysteamine hydrochloride ophthalmic formulation. The trial results showed that the viscous cysteamine eye drops effectively reduced the corneal crystal density, photophobia, corneal cystine crystal scores (CCCS), and corneal crystal depth [10].
Despite an improvement in the prognosis of cystinosis over the years due to the availability of oral and topical cysteamine treatments, early initiation of these treatments and a high level of adherence are critical to delaying disease progression [12]. Stringent adherence to treatment is also essential to ensure long-term organ protection and an improvement in QoL. Ariceta et al. have evaluated the adherence to CYSTAGON® treatment in 34 cystinosis patients through a voluntary, anonymous survey. Treatment was administered by mothers (100%) or fathers (83%) to children less than 11 years old. However, less parental involvement was seen for patients over 11 years of age, and the treatment was primarily self-administered. The study revealed that, while 94% of the patients under 11 adhered to the CYSTAGON® treatment as prescribed, only 50% of the older patients demonstrated a high level of adherence, with the rest reporting frequent schedule changes, missed doses, never using recommended doses, and not caring about the drug prescription. This study identified a decline in the treatment adherence level in teenagers and adults as a significant concern [14].
The aim of this study was to assess the level of adherence to cysteamine therapy among cystinosis patients in Saudi Arabia and its impact on the QoL. Through this study, we would like to evaluate the relationship between adherence to cysteamine therapy and the overall well-being of cystinosis patients in the Saudi Arabian context.
2. Materials and Methods
2.1. Study Design and Population
This prospective cohort study was conducted at the Department of Nephrology at King Faisal Specialist Hospital and Research Center (KFSH&RC) in Riyadh, Saudi Arabia. Patients of all ages, male or female, with an established diagnosis of cystinosis and receiving cysteamine therapy were included in the study.
2.2. Data Collection
This study was approved by the Office of Research Affairs at KFSH&RC. Electronic Medical Files of patients with cystinosis who had visited the Nephrology Clinic at KFSH&RC were reviewed. Demographic data of patients, details related to cysteamine treatment (starting date, type of treatment, dosage, and frequency), and information about any other therapeutic medications the patients were taking were systematically collected. Patients or their parents underwent telephonic interviews, during which we also obtained informed consent for their participation in this study. Adherence to cysteamine therapy (oral therapy and eye drops) was assessed using two measures, Morisky Medication Adherence Scale-8 (MMAS-8) and Medication Possession Ratio (MPR).
The MMAS-8 is a structured, self-reported measure that evaluates the level of treatment adherence. The scale ranges from 0 to 8, where a score of 8 indicates high adherence, 6 to 8 reflects medium adherence, and a score below 6 suggests low adherence. The scale was analyzed using the Morisky Widget software, Chicago, IL, USA [15].
The second measure was medication possession ratio (MPR) that measures the percentage of time a patient has access to medication through the following formula [16]:
MPR of less than 50% indicates low adherence, 50–75% indicates moderate adherence, 76–95% indicates good adherence, and 96–100% indicates excellent adherence.
We also evaluated patients’ health-related QoL using the 36-Item Short Form Health Survey (SF-36). It is a self-reported survey that measures the health outcome using eight main domains: physical functioning, bodily pain, role limitations due to physical health, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions [17].
2.3. Statistical Analysis
Continuous variables were presented as mean or median as appropriate based on the normality of the data, and categorical data were presented as proportions. Descriptive data on adherence to oral cysteamine tablets and topical eye drops were analyzed based on the MPR calculations and responses to the MMAS-8. The overall QoL evaluation was derived from the SF-36 responses.
3. Results
3.1. Patient Recruitment and Baseline Characteristics
The patient recruitment scheme is depicted in Figure 1. Twenty-five cystinosis patients were included in the final analysis. The baseline characteristics of the study participants are summarized in Table 1. The mean age of the patients was 19.04 years (standard deviation [SD] = 6.78), and the majority of patients were female (64%). Barring 2 patients, the remaining 23 (92%) were prescribed oral IR cysteamine therapy, and only about half (13/25; 52%) were prescribed cysteamine eye drops.
3.2. Evaluating the Level of Adherence: MMAS-8 Responses
Of the 25 patients, 15 completed and responded to the MMAS-8 questionnaires. Their responses and corresponding adherence scores are listed in Table 2. The MMAS-8 score analysis revealed that, among the 15 respondents, only 4 (26.7%) demonstrated high adherence to cysteamine therapy, achieving a score of 8. Also, four respondents (26.7%) were categorized as having low adherence with a score < 6. Most of the respondents (n = 7; 46.7%) exhibited a medium level of adherence, achieving scores ranging between 6 and 7.
3.3. Evaluating the Level of Adherence: MPR Analysis
The adherence to cysteamine therapy was additionally assessed through the MPR (Table 3). For oral cysteamine therapy, 6/23 patients (26.1%) were found to be highly adherent to oral cysteamine treatment, showing an MPR of 96–100%, followed by 5/23 patients (21.7%) with an MPR of 76–95%. However, 21.7% of the patients (5/23) were also found to exhibit a low adherence to oral cysteamine therapy, with MPR less than 50%.
Interestingly, none of the 13 patients prescribed cysteamine eye drops fit the excellent adherence category (MPR of 96–100%) for the topical treatment. Although most patients (5/13; 38.4%) exhibited good adherence (MPR of 76–95%), about 30.8% of the patients (4/13) were found to show only moderate or low levels of adherence to the ophthalmic cysteamine treatment with an MPR ranging between <50 and 75%.
Also, a total of 8 patients from both the oral and ophthalmic cysteamine treatment groups were found to have an MPR exceeding 100% due to overfilling of prescriptions, with 5 patients and 3 patients from the 2 groups filling once per year.
3.4. Evaluating the Health-Related QoL: SF-36 Responses
Twenty-two participants of the twenty-five responded to the SF-36 questionnaire. Their responses for the 36 items on the SF-36 were analyzed, and the mean score for each of the eight domains that impact patients’ health-related QoL was computed (Table 4) [17,18].
The mean (±SD) SF-36 scores for the eight domains varied, ranging from 59.66 (±24.38) for ‘social functioning’ to 82.55 (±20.6) for ‘emotional well-being’. The two domains from the SF-36 survey that were the most impacted among the cystinosis patients were ‘social functioning’ and ‘energy/fatigue’. Within these domains, the key aspects affected were ‘physical health or emotional problems interfering with normal social activities’ and ‘feeling tired and worn out’. Most patients reported experiencing either extreme or frequent interference with their social activities due to physical health concerns or emotional problems. Most patients also reported feeling tired or worn out all the time.
4. Discussion
The availability of cysteamine since the early 1990s has helped improve the prognosis of cystinosis patients by delaying renal and extra-renal complications and prolonging life expectancy. It is available in two formulations: IR and DR.
Langman et al. conducted an open-label, crossover, randomized controlled trial (RCT) to compare the efficacy of the IR and DR formulations. This trial included 43 patients (n = 38 for primary efficacy analysis) with a mean age of 12. It showed that the DR formulation was non-inferior to the IR formulation in terms of efficacy, assessed by measuring the WBC cystine levels at the end of each 3-week crossover period [19]. Moreover, to ensure that the efficacy of the DR formulation is sustained in the long term, Langman et al. extended their study for an additional 2 years. Forty of the forty-one patients who had completed the short-term study opted to enroll in the long-term study. The twice-daily administered DR formulation improved quality of life (QoL) parameters and maintained optimal mean WBC cystine levels. The QoL parameters were assessed using the Pediatric Quality of Life Inventory (PedsQL) questionnaire. A significant change in patients’ social, school, and total functioning was observed immediately after switching from IR to DR formulation, and this improvement was sustained even after 2 years of DR therapy [20].
In a more recent study by van Stein et al., the investigators retrospectively compared the cystine and cysteamine levels in 17 patients after a single dose of IR and DR cysteamine formulations. They found that the DR formulation was as effective as the IR formulation, albeit with fewer side effects. While 88.2% (15/17) of patients experienced gastrointestinal (GI) side effects like nausea, vomiting, abdominal pain, and sulfurous body odor with the IR cysteamine, only 35.3% (6/17) experienced such GI effects, and 29.4% (5/17) of patients experienced sulfurous body odor with the DR cysteamine. Moreover, four of the six patients described the GI side effects to be less severe than what they had experienced with the IR formulation, and three of the five patients described the sulfurous body odor to be less intense with the DR formulation than the IR formulation [21].
Cysteamine treatment, however, is not curative and must be taken lifelong to ensure organ preservation through the continuous depletion of cystine crystals from cells [22]. Stringent adherence to cysteamine treatment is crucial to optimize outcomes and delay disease progression. Non-compliance with the cysteamine treatment jeopardizes its efficacy and compromises the QoL of cystinosis patients. Moreover, treatment non-adherence and the resulting inevitable need for subsequent interventions like kidney transplants impose a financial burden on cystinosis patients as well as the healthcare system [23].
This study shows that sub-optimal adherence to the cysteamine treatment, as assessed by patient-reported MMAS-8 and pharmacy-related MPR measures, is a significant challenge in the management of cystinosis. The evaluation of patient QoL using the SF-36 tool demonstrated that, despite being under treatment, physical health challenges and emotional issues patients face with cystinosis interfere with their ability to engage in everyday social interactions and activities. The patients also reported feeling tired and worn out consistently, underscoring an urgent need to identify the specific problem areas that contribute to non-adherence and design therapeutic management strategies that can address these challenges.
The relatively small sample size used in this study is a limitation. Also, an assessment of intra-leukocyte cystine levels, the current gold standard for monitoring therapy adequacy, was unavailable to us, representing another study limitation [24]. Future studies incorporating this assessment can provide additional insights and more objective evaluations of the extent of cysteamine treatment non-adherence. Adherence assessment used in this study complements cystine testing, as it captures patients’ attitude to treatment beyond the time of cystine testing. Thus, despite the limitations, we believe this study can serve as a foundation for designing larger prospective studies to better understand the precise reasons for non-adherence to cysteamine treatment within the local Saudi population and the Gulf population as a whole.
We would also like to acknowledge the challenges we encountered in patient follow-up. As this study was conducted during the COVID-19 pandemic, we could not conduct face-to-face interviews with the study participants and had to rely exclusively on telephonic interviews. This may have potentially led to some communication gaps and incomplete information sharing by the study participants.
5. Conclusions
This study demonstrates sub-optimal adherence to cysteamine treatment in cystinosis patients from Saudi Arabia. It emphasizes the need to conduct larger prospective studies that incorporate intra-leukocyte cystine level measurements to monitor treatment efficacy as an indirect measure of treatment adherence. Such studies can further elucidate the factors contributing to non-adherence.
Author Contributions
Conceptualization, R.A., N.Z., E.A., H.A. (Hamad Almojalli), K.A., T.A., D.B. and H.A. (Hassan Aleid); formal analysis, H.A. (Hassan Aleid); methodology, R.A., N.Z., E.A., H.A. (Hamad Almojalli), K.A., T.A., D.B. and H.A. (Hassan Aleid); supervision, H.A. (Hassan Aleid); writing—review and editing, H.A. (Hassan Aleid). All authors have read and agreed to the published version of the manuscript.
Funding
Medical editing support was funded by Biologix, KSA, with no influence on the study design or content.
Institutional Review Board Statement
The study was approved by the King Faisal Specialist Hospital and Research Centre ethics committee, Riyadh: approval number # RAC 2181114.
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
All data generated or analyzed during this study are included in this published article.
Acknowledgments
Medical editing support was provided by Preeti Nerurkar of Medcytes, Dubai, UAE. We are grateful for the clinical services provided by the pediatric and adult nephrology and transplant team at KFSH&RC and for their support and cooperation in facilitating the data collection process. We also thank MMAS Research LLC for granting us permission to use the ©Morisky Widget MMAS-8 software, which is protected by U.S. copyright and trademark laws. The necessary authorization for its use, as indicated by copyright registration number TX 8-816-517, was obtained for our study. The 36-item Health Survey (SF-36) that was used to assess the QoL in our study was developed by the RAND corporation as part of the Medical Outcomes Study.
Conflicts of Interest
The authors declare no conflicts of interest.
Abbreviations
ESRD: end-stage renal disease; IR: immediate-release; DR: delayed-release; QoL: quality of life; PedsQL: Pediatric Quality of Life Inventory; CCCS: corneal cystine crystal scores; MMAS-8: Morisky Medication Adherence Scale-8; MPR: Medication Possession Ratio; SF-36: Short Form Health Survey.
References
- Gahl, W.A.; Thoene, J.G.; Schneider, J.A. Cystinosis. N. Engl. J. Med. 2002, 347, 111–121. [Google Scholar] [CrossRef] [PubMed]
- Witt, S.; Kristensen, K.; Hohenfellner, K.; Quitmann, J. Health-related quality of life and patient-reported outcome measurements in patients with cystinosis. JIMD Rep. 2023, 64, 199–211. [Google Scholar] [CrossRef] [PubMed]
- Elmonem, M.A.; Veys, K.R.; Soliman, N.A.; van Dyck, M.; van den Heuvel, L.P.; Levtchenko, E. Cystinosis: A review. Orphanet J. Rare Dis. 2016, 11, 47. [Google Scholar] [CrossRef] [PubMed]
- Medic, G.; van der Weijden, M.; Karabis, A.; Hemels, M. A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis. Curr. Med. Res. Opin. 2017, 33, 2065–2076. [Google Scholar] [CrossRef] [PubMed]
- Brodin-Sartorius, A.; Tête, M.J.; Niaudet, P.; Antignac, C.; Guest, G.; Ottolenghi, C.; Charbit, M.; Moyse, D.; Legendre, C.; Lesavre, P.; et al. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int. 2012, 81, 179–189. [Google Scholar] [CrossRef] [PubMed]
- Cherqui, S. Cysteamine therapy: A treatment for cystinosis, not a cure. Kidney Int. 2012, 81, 127–129. [Google Scholar] [CrossRef] [PubMed]
- European Medicines Agency. Cystagon. 2007. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/cystagon (accessed on 19 December 2023).
- Accessdata.fda.gov. CYSTAGON® (Cysteamine Bitartrate) Capsules 50 mg and 150 mg. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020392s010lbl.pdf (accessed on 22 December 2023).
- Accessdata.fda.gov. PROCYSBI (Cysteamine Bitartrate) Delayed-Release Capsules, for Oral Use. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203389s000lbl.pdf (accessed on 19 December 2023).
- Liang, H.; Labbé, A.; Le Mouhaër, J.; Plisson, C.; Baudouin, C. A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study. Investig. Opthalmology Vis. Sci. 2017, 58, 2275–2283. [Google Scholar] [CrossRef] [PubMed]
- Accessdata.fda.gov. CYSTARAN (Cysteamine Ophthalmic Solution) 0.44%. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/200740s000lbl.pdf (accessed on 19 December 2023).
- Castro-Balado, A.; Mondelo-García, C.; Varela-Rey, I.; Moreda-Vizcaíno, B.; Sierra-Sánchez, J.F.; Rodríguez-Ares, M.T.; Hermelo-Vidal, G.; Zarra-Ferro, I.; González-Barcia, M.; Yebra-Pimentel, E.; et al. Recent Research in Ocular Cystinosis: Drug Delivery Systems, Cysteamine Detection Methods and Future Perspectives. Pharmaceutics 2020, 12, 1177. [Google Scholar] [CrossRef] [PubMed]
- Accessdata.fda.gov. CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37%, for Topical Ophthalmic Use. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211302s000lbl.pdf (accessed on 22 December 2023).
- Ariceta, G.; Lara, E.; Camacho, J.A.; Oppenheimer, F.; Vara, J.; Santos, F.; Muñoz, M.A.; Cantarell, C.; Gil Calvo, M.; Romero, R.; et al. Cysteamine (Cystagon(R)) adherence in patients with cystinosis in Spain: Successful in children and a challenge in adolescents and adults. Nephrol. Dial. Transplant. 2015, 30, 475–480. [Google Scholar] [CrossRef] [PubMed]
- Morisky Medication Adherence Research, L. MORISKY SCALES MMAS-4 & MMAS-8. Available online: https://www.moriskyscale.com/#/ (accessed on 4 January 2024).
- Shah, K.K.; Touchette, D.R.; Marrs, J.C. Research and scholarly methods: Measuring medication adherence. J. Am. Coll. Clin. Pharm. 2023, 6, 416–426. [Google Scholar] [CrossRef]
- RAND Corporation. 36-Item Short Form Survey (SF-36). Available online: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form.html (accessed on 6 January 2024).
- Ware, J.E.; Sherbourne, C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992, 30, 473–483. [Google Scholar] [CrossRef] [PubMed]
- Langman, C.B.; Greenbaum, L.A.; Sarwal, M.; Grimm, P.; Niaudet, P.; Deschênes, G.; Cornelissen, E.; Morin, D.; Cochat, P.; Matossian, D.; et al. A Randomized Controlled Crossover Trial with Delayed-Release Cysteamine Bitartrate in Nephropathic Cystinosis. Clin. J. Am. Soc. Nephrol. 2012, 7, 1112–1120. [Google Scholar] [CrossRef] [PubMed]
- Langman, C.B.; Greenbaum, L.A.; Grimm, P.; Sarwal, M.; Niaudet, P.; Deschenes, G.; Cornelissen, E.A.; Morin, D.; Cochat, P.; Elenberg, E.; et al. Quality of Life is Improved and Kidney Function Preserved in Patients with Nephropathic Cystinosis Treated for 2 Years with Delayed-Release Cysteamine Bitartrate. J. Pediatr. 2014, 165, 528–533.e1. [Google Scholar] [CrossRef] [PubMed]
- van Stein, C.; Klank, S.; Grüneberg, M.; Ottolenghi, C.; Grebe, J.; Reunert, J.; Harms, E.; Marquardt, T. A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis. Orphanet J. Rare Dis. 2021, 16, 387. [Google Scholar] [CrossRef] [PubMed]
- Ariceta, G.; Giordano, V.; Santos, F. Effects of long-term cysteamine treatment in patients with cystinosis. Pediatr. Nephrol. 2019, 34, 571–578. [Google Scholar] [CrossRef]
- Lashilola, S.; Xu, W.; Azimpour, K.; McCarthy, M.; Carlot, S.; Game, D.; van der Voort, J. Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom. BMC Nephrol. 2023, 24, 351. [Google Scholar] [CrossRef] [PubMed]
- Simeoli, R.; Cairoli, S.; Greco, M.; Bellomo, F.; Mancini, A.; Rossi, C.; Dionisi Vici, C.; Emma, F.; Goffredo, B.M. A New and Rapid LC-MS/MS Method for the Determination of Cysteamine Plasma Levels in Cystinosis Patients. Pharmaceuticals 2024, 17, 649. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
Patient recruitment scheme.
Table 1.
Baseline characteristics of the participants (n = 25) of the study.
| Mean + SD * | |
|---|---|
| Age (years) | 19.04 + 6.78 |
| Weights (Kg) | 41.3 + 14.09 |
| Height (cm) | 137.74 + 18.12 |
| N (%) | |
| Gender | |
| Male | 9 (36) |
| Female | 16 (64) |
| Cysteamine therapy | |
| Oral (IR) | 23 (92) |
| Eye drops | 13 (52) |
* SD—Standard Deviation.
Table 2.
Results of the Morisky Medication Adherence Scale-8 (MMAS-8) for each patient.
| Patient No. | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 | Item 7 | Item 8 | Overall |
|---|---|---|---|---|---|---|---|---|---|
| 1 | No (1) | No (1) | No (1) | No (1) | Yes (1) | No (1) | No (1) | Never/rarely (1) | 8 |
| 2 | No (1) | No (1) | No (1) | No (1) | Yes (1) | No (1) | Yes (0) | Never/rarely (1) | 7 |
| 3 | No (1) | No (1) | No (1) | Yes (0) | Yes (1) | No (1) | No (1) | Never/rarely (1) | 7 |
| 4 | No (1) | No (1) | No (1) | No (1) | Yes (1) | No (1) | Yes (0) | Never/rarely (1) | 7 |
| 5 | No (1) | No (1) | No (1) | No (1) | Yes (1) | No (1) | Yes (0) | Never/rarely (1) | 7 |
| 6 | Yes (0) | Yes (0) | No (1) | No (1) | Yes (1) | No (1) | Yes (0) | Sometimes (0.5) | 4.5 |
| 7 | Yes (0) | No (1) | Yes (0) | Yes (0) | No (0) | No (1) | No (1) | Sometimes (0.5) | 3.5 |
| 8 | No (1) | No (1) | No (1) | No (1) | Yes (1) | No (1) | No (1) | Never/rarely (1) | 8 |
| 9 | No (1) | Yes (0) | No (1) | No (1) | No (0) | No (1) | No (1) | Never/rarely (1) | 6 |
| 10 | No (1) | Yes (0) | No (1) | No (1) | Yes (1) | No (1) | Yes (0) | Never/rarely (1) | 6 |
| 11 | No (1) | No (1) | No (1) | No (1) | Yes (1) | No (1) | No (1) | Never/rarely (1) | 8 |
| 12 | Yes (0) | No (1) | Yes (0) | No (1) | Yes (1) | Yes (0) | Yes (0) | Sometimes (0.5) | 3.5 |
| 13 | Yes (0) | No (1) | No (1) | No (1) | Yes (1) | Yes (0) | Yes (0) | Sometimes (0.5) | 4.5 |
| 14 | No (1) | No (1) | Yes (0) | No (1) | Yes (1) | No (1) | No (1) | Sometimes (0.5) | 6.5 |
| 15 | No (1) | No (1) | No (1) | No (1) | Yes (1) | No (1) | No (1) | Never/rarely (1) | 8 |
Table 3.
Assessment of adherence to cysteamine therapy using Medication Possession Ratio (MPR).
| MPR | Oral Cysteamine (n = 23 Patients) N (%) | Cysteamine Eye Drops (n = 13 Patients) N (%) |
|---|---|---|
| Less than 50% | 5 (21.7) | 5 (21.7) |
| 50 to 75% | 3 (13) | 3 (13) |
| 76 to 95% | 5 (21.7) | 5 (21.7) |
| 96 to 100% | 6 (26.1) | 6 (26.1) |
More than 100%
| 4 (17.4) 0 (0) | 4 (17.4) 0 (0) |
Table 4.
Health-related quality of life scores assessed by the 36-Item Short Form Health Survey (SF-36).
Table 4.
Health-related quality of life scores assessed by the 36-Item Short Form Health Survey (SF-36).
| Scale | Mean + STD |
|---|---|
| Physical functioning | 77.73 ± 32.39 |
| Limitations due to physical health | 71.59 ± 39.9 |
| Limitations due to emotional problems | 80.3 ± 39.39 |
| Energy/fatigue | 69.32 ± 24.89 |
| Emotional well-being | 82.55 ± 20.6 |
| Social functioning | 59.66 ± 24.38 |
| Pain | 75 ± 24.64 |
| General health | 74.55 + 24 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Algasem, R.; Zainy, N.; Alsabban, E.; Almojalli, H.; Alhasan, K.; Ali, T.; Broering, D.; Aleid, H. Adherence to Cysteamine Therapy Among Patients Diagnosed with Cystinosis in Saudi Arabia: A Prospective Cohort Study. Pharmacy 2024, 12, 123. https://doi.org/10.3390/pharmacy12040123
AMA Style
Algasem R, Zainy N, Alsabban E, Almojalli H, Alhasan K, Ali T, Broering D, Aleid H. Adherence to Cysteamine Therapy Among Patients Diagnosed with Cystinosis in Saudi Arabia: A Prospective Cohort Study. Pharmacy. 2024; 12(4):123. https://doi.org/10.3390/pharmacy12040123
Chicago/Turabian StyleAlgasem, Reem, Nedaa Zainy, Essam Alsabban, Hamad Almojalli, Khalid Alhasan, Tariq Ali, Deiter Broering, and Hassan Aleid. 2024. "Adherence to Cysteamine Therapy Among Patients Diagnosed with Cystinosis in Saudi Arabia: A Prospective Cohort Study" Pharmacy 12, no. 4: 123. https://doi.org/10.3390/pharmacy12040123
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
